Literature DB >> 31280676

Mesenchymal Stromal Cells Are Retained in the Porcine Renal Cortex Independently of Their Metabolic State After Renal Intra-Arterial Infusion.

Jesus M Sierra-Parraga1,2, Anders Munk3, Christine Andersen3, Stine Lohmann2,3, Cyril Moers4, Carla C Baan1, Rutger J Ploeg5, Merel Pool4, Anna K Keller2, Bjarne K Møller6, Henri Leuvenink4, Martin J Hoogduijn1, Bente Jespersen3, Marco Eijken3,6.   

Abstract

The regenerative capacities of mesenchymal stromal cells (MSCs) make them suitable for renal regenerative therapy. The most common delivery route of MSC is through intravenous infusion, which is associated with off-target distribution. Renal intra-arterial delivery offers a targeted therapy, but limited knowledge is available regarding the fate of MSCs delivered through this route. Therefore, we studied the efficiency and tissue distribution of MSCs after renal intra-arterial delivery to a porcine renal ischemia-reperfusion model. MSCs were isolated from adipose tissue of healthy male pigs, fluorescently labeled and infused into the renal artery of female pigs. Flow cytometry allowed MSC detection and quantification in tissue and blood. In addition, quantitative polymerase chain reaction was used to trace MSCs by their Y-chromosome. During infusion, a minor number of MSCs left the kidney through the renal vein, and no MSCs were identified in arterial blood. Ischemic and healthy renal tissues were analyzed 30 min and 8 h after infusion, and 1-4 × 104 MSCs per gram of tissue were detected, predominantly, in the renal cortex, with a viability >70%. Confocal microscopy demonstrated mainly glomerular localization of MSCs, but they were also observed in the capillary network around tubuli. The infusion of heat-inactivated (HI) MSCs, which are metabolically inactive, through the renal artery showed that HI-MSCs were distributed in the kidney in a similar manner to regular MSCs, suggesting a passive retention mechanism. Long-term MSC survival was analyzed by Y-chromosome tracing, and demonstrated that a low percentage of the infused MSCs were present in the kidney 14 days after administration, while HI-MSCs were completely undetectable. In conclusion, renal intra-arterial MSC infusion limited off-target engraftment, leading to efficient MSC delivery to the kidney, most of them being cleared within 14 days. MSC retention was independent of the metabolic state of MSC, indicating a passive mechanism.

Entities:  

Keywords:  cell therapy; ischemia–reperfusion injury; mesenchymal stromal cells; porcine model; renal intra-arterial

Year:  2019        PMID: 31280676     DOI: 10.1089/scd.2019.0105

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  10 in total

Review 1.  Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation.

Authors:  Dina Rady; Marwa M S Abbass; Aiah A El-Rashidy; Sara El Moshy; Israa Ahmed Radwan; Christof E Dörfer; Karim M Fawzy El-Sayed
Journal:  Stem Cells Int       Date:  2020-08-11       Impact factor: 5.443

Review 2.  Stem cell-based therapy for human diseases.

Authors:  Duc M Hoang; Phuong T Pham; Trung Q Bach; Anh T L Ngo; Quyen T Nguyen; Trang T K Phan; Giang H Nguyen; Phuong T T Le; Van T Hoang; Nicholas R Forsyth; Michael Heke; Liem Thanh Nguyen
Journal:  Signal Transduct Target Ther       Date:  2022-08-06

Review 3.  Untangling the Knots of Regulatory T Cell Therapy in Solid Organ Transplantation.

Authors:  Gabriel Orozco; Meera Gupta; Roberto Gedaly; Francesc Marti
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

4.  Regenerative Medicine Application of Mesenchymal Stem Cells.

Authors:  Figen Abatay Sel; Fatma Savran Oguz
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 5.  Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation?

Authors:  Andrew Owen; Philip N Newsome
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 6.  Ex-vivo Kidney Machine Perfusion: Therapeutic Potential.

Authors:  Ruta Zulpaite; Povilas Miknevicius; Bettina Leber; Kestutis Strupas; Philipp Stiegler; Peter Schemmer
Journal:  Front Med (Lausanne)       Date:  2021-12-24

Review 7.  Adipose-Derived Stem/Stromal Cells in Kidney Transplantation: Status Quo and Future Perspectives.

Authors:  Gabriele Storti; Evaldo Favi; Francesca Albanesi; Bong-Sung Kim; Valerio Cervelli
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

8.  Dosing Limitation for Intra-Renal Arterial Infusion of Mesenchymal Stromal Cells.

Authors:  Anders Munk; Christina Søndergaard Duvald; Michael Pedersen; Stine Lohmann; Anna Krarup Keller; Bjarne Kuno Møller; Steffen Ringgaard; Niels Henrik Buus; Bente Jespersen; Marco Eijken
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

9.  Reparative effect of mesenchymal stromal cells on endothelial cells after hypoxic and inflammatory injury.

Authors:  Jesus M Sierra-Parraga; Ana Merino; Marco Eijken; Henri Leuvenink; Rutger Ploeg; Bjarne K Møller; Bente Jespersen; Carla C Baan; Martin J Hoogduijn
Journal:  Stem Cell Res Ther       Date:  2020-08-12       Impact factor: 6.832

Review 10.  The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting.

Authors:  Martin J Hoogduijn; Nuria Montserrat; Luc J W van der Laan; Francesco Dazzi; Norberto Perico; Jens Kastrup; Nicholas Gilbo; Rutger J Ploeg; Valerie Roobrouck; Federica Casiraghi; Christian L Johnson; Marcella Franquesa; Marc H Dahlke; Emma Massey; Sarah Hosgood; Marlies E J Reinders
Journal:  Transpl Int       Date:  2020-04-28       Impact factor: 3.782

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.